Department of Traditional Medicine, School of Medicine, Shahed University, 1471, North Kargar, Engelab Square, Tehran, Iran.
Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
BMC Complement Med Ther. 2020 Jul 3;20(1):207. doi: 10.1186/s12906-020-03003-5.
Depression has rapidly progressed worldwide, and the need for an efficient treatment with low side effect has risen. Melissa officinalis L and Lavandula angustifolia Mill have been traditionally used in Asia for the treatment of depression. Many textbooks of traditional Persian medicine refer to these herbs for the treatment of depression while there are no adequate clinical trials to support this claim. The present study aimed to evaluate the efficacy of M. officinalis and L. angustifolia compared to fluoxetine for the treatment of mild to moderate depression in an 8-week randomized, double-blind clinical trial.
Forty-five adult outpatients who met the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) for major depression, were randomly assigned to 3 groups to daily receive either M. officinalis (2 g) or L. angustifolia (2 g) or fluoxetine (20 mg) and were assessed in weeks 0, 2, 4 and 8 by the Hamilton Rating Scale for Depression (HAM-D) including 17 items.
Our study showed that M. officinalis and L. angustifolia effect similar to fluoxetine in mild to moderate depression. (F = 0.131, df = 2,42, p = 0.877).
Due to some restrictions in this study including absence of placebo group, large-scale trials are needed to investigate the anti-depressant effect of these two herbs with more details.
IRCT2014061718126N1 . Registration date: 2015-06-04-"Retrospectively registered".
抑郁症在全球范围内迅速蔓延,因此需要一种副作用低且有效的治疗方法。迷迭香和薰衣草在亚洲传统上被用于治疗抑郁症。许多传统波斯医学教科书都提到这些草药可用于治疗抑郁症,但目前还没有足够的临床试验来支持这一说法。本研究旨在评估迷迭香和薰衣草与氟西汀治疗轻中度抑郁症的疗效,为期 8 周,采用随机、双盲临床试验。
45 名符合《精神障碍诊断与统计手册》第 5 版(DSM-5)中重度抑郁症标准的成年门诊患者被随机分为 3 组,分别接受迷迭香(2g)、薰衣草(2g)或氟西汀(20mg)治疗,在第 0、2、4 和 8 周采用汉密尔顿抑郁量表(HAM-D)进行评估,共 17 项。
我们的研究表明,迷迭香和薰衣草在轻中度抑郁症方面与氟西汀的疗效相似(F=0.131,df=2,42,p=0.877)。
由于本研究存在一些限制,包括缺乏安慰剂组,因此需要进行大规模试验以更详细地研究这两种草药的抗抑郁作用。
IRCT2014061718126N1.注册日期:2015-06-04-“回顾性注册”。